Share this article
Share this article
JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial Operations, and Amy Chandler has been promoted to Executive Vice President (EVP) for Regulatory Affairs and Quality Management Systems. Mr. Schaller s extensive experience overseeing commercial operations, business development and successful product development will be a tremendous asset to Marizyme as we focus on advancing commercial operations and revenue generation in the year ahead, said Dr. Neil J. Campbell, Marizyme s CEO, President and Board Member. His expertise will be invaluable in building Marizym